JERUSALEM--(BUSINESS WIRE)--Intec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, reports financial results for the three and six months ended June 30, 2016.
Highlights of the first six months of 2016 and recent weeks include:
* Initiated patient enrollment in the pivotal Phase III clinical trial for the Accordion Pill Carbidopa/Levodopa, or AP-CDLD, for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients;
* Initiated a clinical development program for AP-CBD/THC, an Accordion Pill platform with the two primary cannabinoids contained in Cannabis sativa for the treatment of various indications, including pain management;
